세계의 감염증 임상시험 시장 보고서(2025년)

Infectious disease clinical trials refers to the structured research studies that evaluate the safety, efficacy, and optimal use of drugs, vaccines, or therapies targeting infectious diseases. These trials follow carefully designed protocols to monitor participants' responses and collect clinical data under controlled conditions. The findings contribute to advancing medical knowledge and supporting the development of effective treatments and preventive measures against infectious diseases.

The main phases of infectious disease clinical trials include phase I, phase II, phase III, and phase IV. Phase I infectious disease refers to the initial stage of clinical trials for a new drug or vaccine, rather than the infection itself. The key indications include human immunodeficiency virus, hepatitis, influenza, tuberculosis, malaria, coronavirus disease of 2019, and others. The types of studies conducted include randomized controlled trials, open label studies, double blind studies, observational studies, and cohort studies. The various drug types include antibiotics, antivirals, antifungals, vaccines, and combination therapies, which are utilized by pharmaceutical companies, biotechnology firms, contract research organizations, academic institutes, and other research entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The infectious disease clinical trials market research report is one of a series of new reports from The Business Research Company that provides infectious disease clinical trials market statistics, including infectious disease clinical trials industry global market size, regional shares, competitors with a infectious disease clinical trials market share, detailed infectious disease clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease clinical trials industry. This infectious disease clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The infectious disease clinical trials market size has grown strongly in recent years. It will grow from $14.14 billion in 2024 to $15.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period is driven by the emergence of novel pathogens, globalization and increased travel, limited access to sanitation in developing regions, rising incidence of antimicrobial resistance, and government vaccination initiatives.

The infectious disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $19.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be connected to growing investment in rapid diagnostic technologies, expansion of genomic surveillance systems, increasing development of novel vaccine platforms, rising collaborations between pharma and biotech companies, and demand for point of care infectious disease testing. Major trends in the forecast period include use of artificial intelligence in outbreak prediction, adoption of telehealth for infectious disease management, integration of wearable health monitoring devices, focus on one health approaches linking human and animal health, and expansion of digital epidemiology using big data.

The rising healthcare infrastructure is expected to support the growth of the infectious disease clinical trials market going forward. Healthcare infrastructure refers to the physical facilities, medical equipment, technologies, and trained workforce that enable the delivery of healthcare services and support effective disease prevention, diagnosis, and treatment. The development of healthcare infrastructure is increasing due to the growing demand for advanced medical services, the rising burden of emerging and complex diseases, and the need for well-equipped facilities and skilled healthcare professionals to provide timely diagnosis, treatment, and preventive care. Healthcare infrastructure strengthens clinical trial capacity by offering advanced medical facilities, specialized equipment, and improved research capabilities essential for conducting comprehensive infectious disease studies. For instance, in January 2025, according to the American Hospital Association, a United States-based nonprofit organization, the total number of hospitals in the country was 6,090 in 2021 and is projected to reach 6,093 by 2025, indicating modest growth in healthcare facilities nationwide. Therefore, the rising healthcare infrastructure is supporting the growth of the infectious disease clinical trials market.

Leading companies in the infectious disease clinical trials market are emphasizing the development of advanced research programs, such as phase 3 trials of antibiotic candidates, to identify rare side effects and determine optimal dosage levels. A phase 3 trial of antibiotic candidates represents a late-stage clinical study conducted on a large patient population to assess the drug's safety, efficacy, and comparative performance against existing treatments before regulatory approval. For example, in May 2025, Roche, a Switzerland-based pharmaceutical firm, initiated a Phase 3 clinical trial for zosurabalpin, an innovative tethered macrocyclic peptide antibiotic developed to target CRAB, a major cause of severe hospital-acquired infections globally. Zosurabalpin features a unique mechanism of action that inhibits the transport of lipopolysaccharide required for constructing the bacterial outer membrane, with no observed resistance to date. The international trial will include about 400 patients to assess its safety and efficacy relative to standard therapies. Preliminary findings have demonstrated strong activity against multidrug-resistant bacteria, high tolerability, and favorable pharmacokinetic characteristics, positioning zosurabalpin as a potentially transformative solution to the growing threat of antibiotic resistance.

In February 2025, Flourish Research LLC, a US-based multi-site clinical trial organization, acquired Diablo Clinical Research LLC for an undisclosed amount. Through this acquisition, Flourish Research LLC aims to broaden its geographic presence and diversify its therapeutic area expertise to further enhance its clinical trial capabilities. Diablo Clinical Research LLC is a US-based company that conducts infectious disease clinical trials.

Major players operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

North America was the largest region in the infectious disease clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the infectious disease clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The infectious disease clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and enrolment, data collection and management, laboratory testing and analysis, monitoring and safety oversight and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Infectious Disease Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on infectious disease clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for infectious disease clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infectious disease clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Phase: Phase I, Phase II, Phase III, Phase IV
• 2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications
• 3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies
• 4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies
• 5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users
• Subsegments:
• 1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies
• 2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies
• 3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies
• 4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies
• Companies Mentioned: GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Infectious Disease Clinical Trials Market Characteristics

3. Infectious Disease Clinical Trials Market Trends And Strategies

4. Infectious Disease Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Infectious Disease Clinical Trials Growth Analysis And Strategic Analysis Framework

• 5.1. Global Infectious Disease Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Infectious Disease Clinical Trials Market Growth Rate Analysis
• 5.4. Global Infectious Disease Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Infectious Disease Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Infectious Disease Clinical Trials Total Addressable Market (TAM)

6. Infectious Disease Clinical Trials Market Segmentation

• 6.1. Global Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Immunodeficiency Virus
• Hepatitis
• Influenza
• Tuberculosis
• Malaria
• Coronavirus Disease Of 2019 (COVID-19)
• Other Indications
• 6.3. Global Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Randomized Controlled Trials
• Open Label Studies
• Double Blind Studies
• Observational Studies
• Cohort Studies
• 6.4. Global Infectious Disease Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antivirals
• Antifungals
• Vaccines
• Combination Therapies
• 6.5. Global Infectious Disease Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Academic Institutes
• Other End-Users
• 6.6. Global Infectious Disease Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healthy Volunteer Trials
• Dose Escalation Studies
• Safety And Tolerability Studies
• Pharmacokinetic And Pharmacodynamic Studies
• 6.7. Global Infectious Disease Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Efficacy Studies
• Proof Of Concept Studies
• Patient Population Specific Studies
• Short Term Safety Studies
• 6.8. Global Infectious Disease Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Large Scale Efficacy Trials
• Comparative Effectiveness Studies
• Multi Center Clinical Trials
• Extended Safety And Tolerability Studies
• 6.9. Global Infectious Disease Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post Marketing Surveillance Studies
• Long Term Safety Studies
• Real World Evidence Studies
• Special Population Studies

7. Infectious Disease Clinical Trials Market Regional And Country Analysis

• 7.1. Global Infectious Disease Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Infectious Disease Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Infectious Disease Clinical Trials Market

• 8.1. Asia-Pacific Infectious Disease Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Infectious Disease Clinical Trials Market

• 9.1. China Infectious Disease Clinical Trials Market Overview
• 9.2. China Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Infectious Disease Clinical Trials Market

• 10.1. India Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Infectious Disease Clinical Trials Market

• 11.1. Japan Infectious Disease Clinical Trials Market Overview
• 11.2. Japan Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Infectious Disease Clinical Trials Market

• 12.1. Australia Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Infectious Disease Clinical Trials Market

• 13.1. Indonesia Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Infectious Disease Clinical Trials Market

• 14.1. South Korea Infectious Disease Clinical Trials Market Overview
• 14.2. South Korea Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Infectious Disease Clinical Trials Market

• 15.1. Western Europe Infectious Disease Clinical Trials Market Overview
• 15.2. Western Europe Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Infectious Disease Clinical Trials Market

• 16.1. UK Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Infectious Disease Clinical Trials Market

• 17.1. Germany Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Infectious Disease Clinical Trials Market

• 18.1. France Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Infectious Disease Clinical Trials Market

• 19.1. Italy Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Infectious Disease Clinical Trials Market

• 20.1. Spain Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Infectious Disease Clinical Trials Market

• 21.1. Eastern Europe Infectious Disease Clinical Trials Market Overview
• 21.2. Eastern Europe Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Infectious Disease Clinical Trials Market

• 22.1. Russia Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Infectious Disease Clinical Trials Market

• 23.1. North America Infectious Disease Clinical Trials Market Overview
• 23.2. North America Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Infectious Disease Clinical Trials Market

• 24.1. USA Infectious Disease Clinical Trials Market Overview
• 24.2. USA Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Infectious Disease Clinical Trials Market

• 25.1. Canada Infectious Disease Clinical Trials Market Overview
• 25.2. Canada Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Infectious Disease Clinical Trials Market

• 26.1. South America Infectious Disease Clinical Trials Market Overview
• 26.2. South America Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Infectious Disease Clinical Trials Market

• 27.1. Brazil Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Infectious Disease Clinical Trials Market

• 28.1. Middle East Infectious Disease Clinical Trials Market Overview
• 28.2. Middle East Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Infectious Disease Clinical Trials Market

• 29.1. Africa Infectious Disease Clinical Trials Market Overview
• 29.2. Africa Infectious Disease Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Infectious Disease Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Infectious Disease Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Infectious Disease Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. Infectious Disease Clinical Trials Market Competitive Landscape
• 30.2. Infectious Disease Clinical Trials Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc (GSK) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Moderna Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Infectious Disease Clinical Trials Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Merck & Co Inc
• 31.3. Gilead Sciences Inc
• 31.4. AbbVie Inc
• 31.5. Eli Lilly and Company
• 31.6. Bristol Myers Squibb Company
• 31.7. Roche Holding AG
• 31.8. Bayer AG
• 31.9. Takeda Pharmaceutical Company Limited
• 31.10. CSL Limited
• 31.11. Regeneron Pharmaceuticals Inc
• 31.12. Biogen Inc
• 31.13. Amgen Inc
• 31.14. Inovio Pharmaceuticals Inc
• 31.15. Dynavax Technologies Corporation

32. Global Infectious Disease Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Infectious Disease Clinical Trials Market

34. Recent Developments In The Infectious Disease Clinical Trials Market

35. Infectious Disease Clinical Trials Market High Potential Countries, Segments and Strategies

• 35.1 Infectious Disease Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Infectious Disease Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Infectious Disease Clinical Trials Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer